Journal article
Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities
DA Helb, KKA Tetteh, PL Felgner, J Skinner, A Hubbard, E Arinaitwe, H Mayanja-Kizza, I Ssewanyana, MR Kamya, JG Beeson, J Tappero, DL Smith, PD Crompton, PJ Rosenthal, G Dorsey, CJ Drakeley, B Greenhouse, JC Rayner
Proceedings of the National Academy of Sciences of the United States of America | NATL ACAD SCIENCES | Published : 2015
Abstract
Tools to reliably measure Plasmodium falciparum (Pf) exposure in individuals and communities are needed to guide and evaluate malaria control interventions. Serologic assays can potentially produce precise exposure estimates at low cost; however, current approaches based on responses to a few characterized antigens are not designed to estimate exposure in individuals. Pf-specific antibody responses differ by antigen, suggesting that selection of antigens with defined kinetic profiles will improve estimates of Pf exposure. To identify novel serologic biomarkers of malaria exposure, we evaluated responses to 856 Pf antigens by protein microarray in 186 Ugandan children, for whom detailed Pf ex..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
We thank the individuals who participated in this study and their families. We also thank Rie Sasaki, Li Liang, and Jozelyn Pablo for cloning and generating the microarray data, Robin Anders and Christine Langer for providing recombinant proteins, and Nathan Woody for image production. We thank the study team and the Makerere University-University of California, San Francisco Research Collaboration and Infectious Diseases Research Collaboration for administrative and technical support. This research has been supported by the President's Emergency Plan for AIDS Relief through Centers for Disease Control and Prevention Cooperative Agreement Number OCCU024421, the NIH as part of International Centers of Excellence in Malaria Research Program U19AI089674, and the Doris Duke Charitable Foundation. J.S. and P.D.C. are supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH. J.G.B. was supported by the National Health and Medical Research Council of Australia. B.G. is the recipient of a Doris Duke Clinical Scientist Development Award. The Burnet Institute is supported by National Health and Medical Research Council Independent Research Institutes Infrastructure Support Scheme and a Victoria State Government Operational Infrastructure Support Grant.